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Abstract
Background: Pre- and postconditioning describe mechanisms whereby short ischemic periods protect an organ
against a longer period of ischemia. Interestingly, short ischemic periods of a limb, in itself harmless, may increase
the ischemia tolerance of remote organs, e.g. the heart (remote conditioning, RC). Although several studies have
shown reduced biomarker release by RC, a reduction of complications and improvement of patient outcome still
has to be demonstrated. Atrial fibrillation (AF) is one of the most common complications after coronary artery
bypass graft surgery (CABG), affecting 27-46% of patients. It is associated with increased mortality, adverse
cardiovascular events, and prolonged in-hospital stay. We hypothesize that remote ischemic pre- and/or post-
conditioning reduce the incidence of AF following CABG, and improve patient outcome.
Methods/design: This study is a randomized, controlled, patient and investigator blinded multicenter trial. Elective
CABG patients are randomized to one of the following four groups: 1) control, 2) remote ischemic preconditioning,
3) remote ischemic postconditioning, or 4) remote ischemic pre- and postconditioning. Remote conditioning is
applied at the arm by 3 cycles of 5 minutes of ischemia and reperfusion. Primary endpoint is the incidence AF in
the first 72 hours after surgery, detected using a Holter-monitor. Secondary endpoints include length-of-stay on the
intensive care unit and in-hospital, and the occurrence of major adverse cardiovascular events at 30 days, 3 months
and 1 year.
Based on an expected incidence in the control group of 27%, 195 patients per group are needed to detect with
80% power a reduction by 45% following either pre- or postconditioning, while allowing for a 10% dropout and at
an alpha of 0.05. With the combined intervention expected to be stronger, we need 75 patients in this group to
detect a reduction in incidence of AF of 60%.
Discussion: The RICO-trial (the effect of Remote Ischemic Conditioning on atrial fibrillation and Outcome) is a
randomized controlled multicenter trial, designed to investigate whether remote ischemic pre- and/or post-
conditioning of the arm reduce the incidence of AF following CABG surgery.
Trial registration: ClinicalTrials.gov under NCT01107184.
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Background
It has been demonstrated previously that an organ can
develop tolerance against ischemic stress by different
interventions. In experimental studies, short periods (e.
g., 3-5 minutes) of myocardial ischemia before the sus-
tained ischemic period significantly reduced infarct size
(early and late preconditioning) [1-3]. In addition, there
is a significant amount of tissue that is damaged during
early reperfusion, and it has been shown that staged
reperfusion or short periods of ischemia (seconds to
minutes) at the start of reperfusion, limits tissue damage
(postconditioning) [4-6].
Besides periods of ischemia, several drugs may also
induce this organ tolerance by pre- and postconditioning.
These include nitrates, [7,8] opioids, [9,10] volatile anaes-
thetics [11-13] and noble gases [14,15]. While the applica-
tion of short periods of organ ischemia is quite invasive
and in most clinical settings not feasible, the named drugs
mostly have significant hemodynamic or neurologic
(anaesthetic) side effects preventing their use in a broad
patient population (also outside the operating theatre).
Recently, a fascinating possibility to protect tissue
against ischemia-reperfusion damage has been described.
Remote ischemic pre- and postconditioning refer to the
protective effect on the heart that can be induced by
submitting another organ or skeletal muscle to multiple
short periods of ischemia and reperfusion. Studies in
animals have shown a reduction in infarct size after
short periods of preconditioning ischemia (RIPC) on a
remote organ [16,17]. In addition, clamping and releas-
ing the femoral or renal artery before the onset of reper-
fusion can reduce myocardial infarct size (remote
postconditioning, RpostC); [18] multiple cycles of ische-
mia reperfusion applied to the hind limb during myo-
cardial reperfusion reduced infarct size in rabbits and
pigs [19,20].
In humans, RIPC by short-term non-invasive limb
ischemia reduced troponin I release after elective percu-
taneous coronary intervention (PCI) [21]. In patients
subjected to coronary artery bypass graft (CABG) sur-
gery, RIPC reduced myocardial damage as measured by
biomarker release [22,23]. RpostC at the onset of reper-
fusion protected human endothelium against ischemia
reperfusion injury [24]. Recently, this was translated to
patients with acute myocardial infarction: applying short
periods of forearm ischemia-reperfusion in patients with
acute coronary syndrome by ambulance personal during
transport to the hospital reduced infarct size as mea-
sured by cardiac perfusion scintigraphy [25].
Until today it is not known whether the reduction in
tissue damage and reduced biomarker release will trans-
late into better outcome of these patients. If an easily
applicable procedure like remote conditioning leads to
improved outcome in patients with planned or acute
ischemic periods, such an intervention would be of
great help in patient care. Hoole et al. demonstrated a
reduction of major adverse cardiac events (MACE) after
RIPC in patients undergoing elective PCI [21]. The role
of RIPC and RpostC in the reduction of perioperative
arrhythmias is unknown. Therefore, the present study
investigates for the first time the long-time effects of
RIPC, RpostC, and the combination of both procedures,
in patients subjected to CABG surgery.
Atrial fibrillation (AF) is one of the most common
complications after CABG surgery, affecting 27-46% of
patients. It is associated with increased mortality,
adverse cardiovascular events, and prolonged in-hospital
stay. We hypothesize that RIPC and/or RpostC reduce
the incidence of AF following CABG, and improve
patient outcome.
Methods/design
Study objectives
The objective of this study is to investigate whether the
safe and simple intervention of remote ischemic condi-
tioning, (pre-, post-conditioning, or both), improves
clinical outcome after CABG surgery, as measured by
the incidence of postoperative atrial fibrillation, the
length of stay on the intensive care unit (ICU) and in-
hospital length of stay, and the occurrence of MACE at
follow up.
Study design
The RICO-trial is a randomized controlled multi-centre
trial, utilizing four parallel arms. Patients are blinded for
the treatment allocation since the study intervention will
be done under general anaesthesia. In addition, investi-
gators analyzing the data will be blinded and statistical
analysis will be done using coded treatment groups,
which will only be revealed after the analysis. However,
local investigators responsible for inclusion of patients
and executing the study protocol, will not be blinded
Patients scheduled for an elective, isolated CABG pro-
cedure, will be eligible. After inclusion, subjects will be
randomized to one of the following arms 1) control, 2)
remote ischemic preconditioning (RIPC), 3) remote
ischemic postconditioning (RpostC), or 4) remote
ischemic pre- and postconditioning (RIPC+RpostC).
Randomization will be done using an internet based
randomization application, with a biased coin approach
and stratified for participating centre.
Ethics
The study will be conducted in accordance with the
principles of the Declaration of Helsinki, the Medical
Research Involving Human Subjects Act (WMO) and
the principles of “good clinical practice”. The indepen-
dent medical ethics committee of the Academic Medical
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Center in Amsterdam has approved the study for the
hospitals in the Netherlands (approval number
09.017.1769, trial number MEC09/186), and the inde-
pendent medical ethics committees of the centres in
Belgium and Germany for these respective centres.
Written informed consent is obtained from all partici-
pating patients.
The study is registered at ClinicalTrials.gov under
NCT01107184.
Participating centres
Patients will be enrolled in at least six centres; two aca-
demic centres and one non-academic centre in the
Netherlands, two academic centres in Belgium and one
academic centre in Germany.
Study population
The study population consists of patients scheduled for
elective CABG surgery in one of the participating
centres.
Inclusion criteria are: elective CABG without valve
surgery, the use of extra corporeal circulation, >18 years
of age.
Exclusion criteria are: prior cardiac surgery, a history
of AF, use of a class 1 or 3 anti arrhythmic drug or
digoxin, intermittent aortic cross clamping during sur-
gery, left ventricular ejection fraction ≤30%, serious pul-
monary disease, renal failure, liver failure and the use of
glibenclamide.
Study outline
Local researchers will recruit and randomize patients,
perform the study intervention, collect baseline, peri-
operative and follow-up data and take care of the Hol-
ter-monitoring. Depending on the centre, patients will
be screened and asked for consent either during the
outpatient screening or while hospitalized prior to sur-
gery. Randomization will be done after inclusion and
prior to surgery.
All patients will have a surgical tourniquet placed on
the upper arm prior to surgery. These tourniquets,
which are also used in orthopaedic surgery to create a
bloodless operating field, use compressed air and can
create and maintain a preset pressure. Patients in the
RIPC group and in the RIPC+RpostC group will have
their tourniquet inflated to 200 mmHg for 3 × 5 min-
utes after the induction of anaesthesia but before the
start of cardiopulmonary bypass. During aortic cross-
clamp, patients in both the RpostC group and the RIPC
+RpostC group will have their tourniquet inflated for 3
× 5 minutes. In the control group, no tourniquet inflat-
ing will be done. Peripheral saturation and invasive
blood pressure monitoring will be done using the
contra-lateral arm, so that ischemic conditioning will
not hinder monitoring. Anaesthesia
Anaesthesia will be performed according to good clini-
cal standard procedures. Patients will be pre-medicated
with midazolam 7.5 mg p.o. Induction of anaesthesia
will be with intravenously (i.v.) applied midazolam 0,1-
0,2 mg/kg and/or propofol TCI, i.v. sufentanil 1,0-1,5
μg/kg and i.v. rocuronium 0,6 mg/kg. Continuous infu-
sion of sufentanil (0,3 μg/kg/h) and propofol TCI will be
used for maintenance of anaesthesia; anaesthesia depth
will not be monitored routinely.
Surgery
Surgical procedures include the use of extra corporal
circulation but are otherwise not standardized, except
for the exclusion of intermitted aortic cross clamping.
Peri-operative care will be provided according to local
standards.
Arrhythmias
In case AF develops, the patient should be treated
according to local protocol, which may include either
sotalol or amiodarone, but is not restricted to these
medications. There will be no use of prophylactic medi-
cation for AF (e.g. prophylactic sotalol or amiodarone).
Postoperatively
At the end of surgery, prior to transportation to the
intensive care unit, a Holter-monitor (Spacelabs Lifecard
CF ECG) will be attached to the participants for moni-
toring of postoperative AF. After transportation to the
ICU the monitor will be checked for proper attachment
and thereafter once a day. After 72 hours the monitors
will be collected and the data downloaded.
Follow-up
After discharge from the hospital, the patients will be
contacted at 30 days, 3 months and 1 year after the
initial surgery by phone and requested to fill out a
mailed questionnaire. In addition, patients’ physicians
will be contacted after 1 year to complete the record.
They will be questioned about the occurrence of rhythm
disturbances, heart failure, revascularisation, acute cor-
onary syndrome, myocardial infarction and transient
ischemic attacks and stroke.
Data collection and monitoring
Data of each patient will be noted in an individual case
report form (CRF), identifiable by a study-specific
patient identification number. CRF’s will be stored
locally and send electronically to the AMC. Holter data
will be downloaded from the devices and transported or
send to the AMC for central analysis and storage. Ques-
tionnaires will be mailed to the participants 30 days, 3
months and 1 year after surgery.
There will be regular meetings between the study
coordinators and the main investigators of each site.
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Data analysis
Holter data analysis will be done using Spacelabs Path-
finder Software Kit (version 9.019) and under supervi-
sion of a cardiologist of the Academic Medical Centre
Amsterdam, The Netherlands.
Endpoints
Primary endpoint
The primary endpoint is the percentage of patients that
develop AF during the first 72 hours postoperatively.
Secondary endpoint
Secondary endpoints include the percentage of patients
with AF on each post-operative day, the total duration
of AF and the number of episodes, the length of stay on
the ICU as well as the in hospital stay and the MACE
rate at 30 days, 3 months and 1 year follow-up.
Statistical analysis
Sample size calculation
We hypothesize that pre- or post-conditioning will
decrease the probability of AF by 40 to 50 per cent at a
background rate of 27 per 100 CABG patients treated,
which might be a clinically relevant reduction of AF.
The effort of a combination of pre- and post-condition-
ing may only be relevant if there is additional reduction
of AF, meaning that the combination is even more effec-
tive and might reduce the occurrence of AF by another
15%. In case of the pre- or post-conditioning groups a
reduction in proportion AF from 0.27 to 0.1485 (minus
45%) seems feasible and clinically relevant. In case of
the pre- and post-conditioning group a gain of at least
60%, from 0.27 to 0.108 (minus 60%), is considered
clinically relevant. Sample sizes of 175 patients in the
control group and 175 patients in the pre-conditioning
group achieve 80% power to detect a difference between
the group proportions of -0.1215. The test used is the
two-group Chi2-test with a two-sided 0.05 significance
level. Similarly, the number of patients sampled for the
post-conditioning group should also be 175. With 175
patients in the control group, the number of patients
needed in the pre- and post-conditioning group should
be at least 66 to achieve 80% power to detect a differ-
ence between the group proportions of -0.162, using,
again, a two-group Chi2-test with a two-sided 0.05 sig-
nificance level. To account for 10% possible drop-out of
patients 195 patients are needed in the control group,
the pre-conditioning group, and the post-conditioning
group respectively, while 75 patients are needed in the
pre- and post-conditioning group. In total, 660 patients
are needed.
Discussion
Recently, remote ischemic conditioning gained attention
as a possibility to protect different organs against
ischemia reperfusion injury. Due to the safe and non-
invasive nature of the intervention, this protection
might be applicable in numerous patients. Small studies
in cardiac surgery using biomarker release as endpoint
suggest a beneficial effect of remote conditioning,
[22,23,26-29] although not all studies are positive [30].
Although biomarker release following cardiac surgery is
an accepted surrogate outcome parameter, [31-33] there
is no evidence that remote conditioning leads to an
improved outcome. Therefore, routinely use of remote
conditioning cannot be recommended at this time. A
study investigating the effects of remote ischemic condi-
tioning on outcome parameters such as survival or qual-
ity of life would require a huge number of patients. We
choose post-operative AF as a surrogate endpoint in this
study, since it is not only a predictor of outcome, but
prevention of AF also improves outcome [34-39]. The
aetiology of AF following cardiac surgery is multi-factor-
ial and not fully elucidated; however, ischemia reperfu-
sion injury sustained during clamping of the aorta and
generation of radical oxygen species during reperfusion
play an important role. Ischemic conditioning is known
to improve these processes. Indeed, direct ischemic con-
ditioning has been shown to reduce post-operative
arrhythmias [40-43]. Therefore, we hypothesize that
remote ischemic conditioning can reduce AF.
Most ischemic periods (e.g., acute coronary syndrome,
stroke) are unpredictable, and therefore RIPC is not fea-
sible. A protective measure that can be applied after the
onset of ischemia, such as RpostC, might have greater
clinical implications. We therefore choose to include
next to RIPC also RpostC, which has been demonstrated
to be effective in animal and volunteer studies and a
small trial in patients [18-20,24,44,45]. There is evidence
that in aged or diseased myocardium, the ability to
induce conditioning is reduced [46-48,46,47,49]. There-
fore, we speculate that the added effect of both pre- and
postconditioning could provide an additive protection
not achieved by either intervention alone. Since such an
effect should be more powerful to justify the extra
effort, we expect an increased reduction in AF in the
pre- and postconditioning group and will therefore
include a smaller number of patients in this group.
In conclusion, the RICO-trial is a randomized con-
trolled multicenter trial to investigate whether remote
ischemic conditioning (RIPC, RpostC, or both) can
reduce complications and improve outcome after CABG
surgery.
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